Lexon appeals against £1.2m nortriptyline fine

Pharmaceutical wholesaler Lexon (UK) has filed an appeal against a £1,220,383 fine imposed by the Competition and Markets Authority for allegedly exchanging commercially sensitive information about prices for nortriptyline tablets.

In a decision made in March, the CMA found that between 2015 and 2017, King, Lexon (UK) and Alissa Healthcare Research exchanged commercially sensitive information about prices for nortriptyline tablets, the volumes they were supplying and Alissa’s plans to enter the market.

King was fined £75,573 and Alissa £174,912, with both companies handed reduced fines for admitting the infringement. Lexon did not admit to the infringement, and the CMA imposed a £1,220,383 fine.

An appeal has been filed in the Competition Appeal Tribunal against the CMA’s findings in the infringement decision and the penalty imposed. The CMA has said it will defend the appeal.

Latest discussions

  1. Pre reg exams

    Thanks for your comments both - Richard ...

  2. Pre reg exams

    Having been qualified just over 40 years...

This website is for healthcare professionals, people who work in pharmacy and pharmacy students. By clicking into any content, you confirm this describes you and that you agree to Pharmacy Magazine's Terms of Use and Privacy Policy.

We use essential, performance, functional and advertising cookies to give you a better web experience. Find out how to manage these cookies here. We also use Interest Based Advertising Cookies to display relevant advertisements on this and other websites based on your viewing behaviour. By clicking "Accept" you agree to the use of these Cookies and our Cookie Policy.